亚洲人中黄昏症的诊断和患病率:一个范围审查
Junko Ueshima1, Tatsuro Inoue2, Yoko Saino3
1Department of Nutritional Service, NTT Medical Center Tokyo, Shinagawa, Tokyo, Japan; Palliative and Supportive Medicine, Graduate School of Medicine, Aichi Medical University, Yazakokarimata, Nagakute, Aichi, Japan.
Nutrition (Burbank, Los Angeles County, Calif.)
|December 19, 2023
概括
本范围审查强调了亚洲人群中多样化的诊断标准和缓解症的流行率. 研究表明,癌症和非癌症患者之间的诊断方法和患病率存在显著差异.
科学领域:
- 老年学是指老年学的学科.
- 临床医学 临床医学
- 营养科学 营养科学
背景情况:
- ,一个复杂的代谢综合征,显著影响患有慢性疾病和癌症的患者.
- 准确的诊断和了解患病率对于有效的患者管理至关重要.
- 现有的诊断标准可能无法充分考虑种族人类学差异,特别是在亚洲人群中.
研究的目的:
- 在亚洲成年人中描述卡赫克西亚的诊断标准.
- 为了确定用于缓解症诊断的切断值.
- 确定亚洲患有癌症和其他慢性疾病的人群中黄昏症的患病率.
主要方法:
- 以英语和日语出版的研究的系统范围审查 (2008年12月至2022年4月).
- 包括涉及亚洲成年患者的观察性,纵向性,截面性和临床试验.
- 搜索了六个数据库,选了4131项研究,确定了107篇符合条件的文章 (11篇非癌症,96篇癌症).
主要成果:
- 常见的诊断指标包括减肥,体重指数 (BMI) 和肌肉质量.
- 经过修改的埃文斯标准经常用于非癌症缓冲症;原来的费伦标准用于癌症缓冲症.
- 患病率差异很大:3.4%66.2% (非癌症) 和6.2%93% (癌症). 群体之间的BMI范围有所不同,亚洲特有的切割值的使用有限.
结论:
- 缓冲症的诊断标准,包括BMI和肌肉质量,受到种族人体测量变异的影响.
- 需要更多的研究,利用亚洲人群的特定截止值进行研究.
- 患病率的广泛范围凸显了亚洲不同患者群体中缓解症的异质性.
更多相关视频
03:35Determining Gender-Based Differences in Retinal and Choroidal Thickness in Underweight Individuals via Swept-Source Optical Coherence Tomography
Published on: December 1, 2023
300
07:33Non-invasive Skeletal Muscle Quantification in Small Animals Using Micro-computed Tomography
Published on: November 8, 2024
445
相关概念视频
01:28Anorexia Nervosa
75
Anorexia nervosa is a complex and severe eating disorder characterized by an intense fear of weight gain, an unrelenting pursuit of thinness, and a distorted body image. It often leads to dangerously low body weight relative to an individual's age and height. This disorder is marked by significant physical and psychological consequences, making it one of the most life-threatening psychiatric illnesses.
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
75
01:21Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355